Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Analyses from PALOMA-3

M. Cristofanilli, D. J. Slamon, J. Ro, I. Bondarenko, S. A. Im, N. Masuda, M. Colleoni, A. DeMichele, S. Loi, S. Verma, H. Iwata, N. Harbeck, S. Loibl, F. André, K. Puyana Theall, X. Huang, C. Giorgetti, C. Huang Bartlett, N. C. Turner

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
Pages (from-to)viii708
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume29
DOIs
StatePublished - Oct 1 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this